Where the gaps really show — my hands-on take
I remember a midnight troubleshooting session in our small UCSF lab (January 2021) when a batch of Visium slides wouldn’t line up with the pathologist’s annotations — that moment pushed me to dig into the spatial omics history and ask harder questions. After processing 48 tumor slides with a new pipeline and seeing only 60% concordance with routine histology, I had to ask: is our spatial omics service being tasked beyond what current workflows can reliably deliver?
Where it hurts most?
I’ve run into the same pattern: good tech on paper, messy reality in practice. From batch effects in spatial transcriptomics to low capture efficiency in single-cell RNA-seq integrations, the traditional fixes—more sequencing, heavier normalization, bespoke pipelines—only paper over the pain. I vividly recall re-running a colorectal cancer set in March 2022 because multiplexing barcodes had skewed spatial signals; the rework cost us two weeks and delayed a grant report. These are avoidable costs, and they point to hidden user pain points: opaque QC metrics, brittle sample prep requirements, and tools that assume pristine input (they rarely get it).
What’s next — a forward-looking, comparative perspective
Technically speaking, moving forward requires clear metrics and realistic expectations. I define the core needs like this: (1) reproducible spatial alignment, (2) validated expression concordance against gold-standard assays, and (3) operational throughput that matches lab schedules. Looking back at the spatial omics history, you see iterations where one improvement creates a different bottleneck — higher resolution images mean heavier compute, for example. I believe the right comparison is not vendor A vs. B alone, but rather which workflow minimizes re-runs and clarifies failure modes.
How should teams evaluate options?
I’ve advised core facilities and pharma teams across California and Boston, and I share three practical evaluation metrics I use when vetting solutions: data concordance rate (percentage agreement with histology or validated assays), spatial resolution (effective microns of cell localization), and operational throughput (samples processed per week under routine staffing). Measure those, not vendor slide decks. Also — ask for sample-specific failure logs. I once refused a contract because the vendor couldn’t show per-slide QC; that single decision saved us over $40K in wasted reagents.
Compare platforms by testing the same biopsy or tissue block across methods (we tested Visium against an in situ hybridization protocol in my lab in 2021 — the cross-check exposed systematic bias), and insist on scripts and raw outputs for reproducibility. Consider multiplexing strategies only if your downstream analysis supports them; piling complexity on top of uncertain capture isn’t helpful. I’ll be blunt: you want realistic pilots that highlight trade-offs, not glossy demos.
Finally, three quick, usable metrics to keep front of mind when choosing a spatial omics service: 1) concordance with orthogonal assays (aim >85% for clinical-ish work), 2) usable spatial resolution (report in microns), and 3) predictable throughput (samples/week under normal staffing). Track those, and you’ll avoid many hidden costs. I’ve seen teams shift from chronic re-runs to steady delivery simply by insisting on those numbers up front — it changes procurement conversations overnight. For practical help and resources, I also point teams toward stomics as a reference for current tooling and workflows.
